prostaCare has finished phase 1 - the feasibility study and is now laying the groundwork for its commercial success by engineering the final device in Germany and targeting a CE mark achieved in Europe first through a regulatory trial in Germany and in Singapore. Post this we target three markets to launch the treatment – Germany for central Europe, Singapore for Asia and then Australia.
Like this, we will not only be able to use our invested money best but most importantly ensure the quality of our device and treatment and at the same time having a fast route to the market. This is indeed our first guiding principle - the quality of the device and treatment solution.
In those first markets we first target privately paying patients who can afford the early price point and will help the company finetuning its business model and scaling up the production for more quantities.
Once we have mastered this we can embark on other major trials and launch in the other big global markets such as in North America, in China, in Eastern Europe and South America.
Having said all this, we have enough "low hanging fruit" to pick already in our early launch markets.